|
AstraZeneca praises
UAE for vaccination rollout
and testing strategy
(Dubai,
UAE) -
A Government Affairs
Director from AstraZeneca,
the developer of one of the
leading COVID-19 vaccines in
partnership with Oxford
University, has praised the
UAE’s vaccine rollout
program by highlighting the
work done by health
authorities in the region to
make vaccines available as
soon as possible.
To
date, over 12.1 million
vaccination doses have been
administered in the UAE with
a vaccine distribution rate
of over 124 doses per 100
people, with approximately
70,000 doses of the vaccine
administered daily. In terms
of population vaccinated,
the UAE is currently fourth
after the Seychelles,
Maldives and Israel.
Qutaiba Al Manaseer,
Government Affairs Director,
Middle East and Africa,
AstraZeneca, said: Middle
East countries have been
successful in their efforts
to make vaccines available
as soon as possible. Health
authorities across the
region have developed agile
regulatory systems and
adapted rolling review
strategies to ensure a fast
but thorough regulatory
process.
“Specifically, the UAE ranks
among the best in the world
in terms of the speed of its
vaccination programme. This
is attributed to strong
efforts from key senior
stakeholders who worked
collaboratively with health
authorities to deliver
impactful campaigns that are
aimed at increasing the
trust in the safety of
vaccines available in the
country, and uptake from the
local population,” added Al
Manaseer.
The
comments were made ahead of
the inaugural Pharma and
Drug Discovery Conference to
be held on the opening day
of Arab Health, which takes
place from 21-24 June 2021
at the Dubai World Trade
Centre. During the
conference, Mr Al Manaseer
will be presenting the
session Oxford University
and AstraZeneca partnership
towards broad and equitable
access to COVID-19 Vaccine.
"From the start of
the pandemic, AstraZeneca's
approach has focused on
partnering with scientists,
governments, multilateral
organisations and
manufacturers to establish
agreements for the
development and supply of
our vaccine, and to fight
the pandemic, together,”
said Al Manaseer.
“At AstraZeneca, we were
proud to be the first global
pharmaceutical company to
join COVAX in June 2020.
Through the initiative, we
are partnering with CEPI,
Gavi, the WhO, UNICEF and
PAHO and our subscribing
partner, the Serum Institue
of India, to enable
equitable and global access
to our vaccine. Together, we
have already delivered 37
million doses of our
vaccine, including critical
deliveries to countries in
the Middle East. It is only
through effective
partnerships that reaching
these milestones was made
possible," he added.
Among the experts presenting
at the Pharma & Drug
Discovery Conference, are Dr
Yang Xiaoming, Chairman of
the China National Biotech
Group (CNBG), Prof Graham
Ball, Professor of
Bioinformatics, Nottingham
and Trent University, UK,
and Prof Mirza Baig,
Professor and Chairman of
Clinical Pharmacy and
Pharmacotherapeutics, Dubai
Pharmacy College for Girls.
Other notable insights
will be delivered by from
Prof Peter Hotez, Director,
Texas Children's Center for
Vaccine Development (CVD),
Dean, National School of
Tropical Medicine, Professor
of Paediatrics ad Molecular
Virology & Microbiology,
Baylor College of Medicine,
Prof Dr Stefan H.E Kaufman,
Director and Scientific
Member, Max Planck Institut
for Infection Biology, Prof
Dr Mohammad Semreen,
Professor and Chairman of
Medicinal Chemistry
Department, College of
Pharmacy, University
Sharjah, Prof Dr Gunnveig
Grodeland, Senior Researcher
and Group Leader, Oslo
University Hospital Oslo and
Farshad Guirakhoo, Chief
Scientific Officer, COVAXX,
United Biomedical, Chief
Scientific Officer,
Vaxxinity.
The
conference will be chaired
by Dr Mohammed Al-Gamal,
Associate Professor, College
of Pharmacy, Medicinal
Chemistry, Group
Coordinator, Drug Design and
Discovery Group, University
of Sharjah.
“Drug
development has been at the
forefront of the news agenda
for almost 18 months and
will continue to be a topic
of discussion for the
foreseeable future. At Arab
Health we are committed to
addressing the most relevant
topics in the healthcare
sector and as such have
brought together global
experts to inform and shape
the future of innovative
models in drug discovery,”
said Ross Williams,
Exhibition Director at Arab
Health.
Arab Health
has been developed under the
show theme of ‘United by
Business, driving the
industry forward’, with the
live, in-person event
expected to welcome 3,500
exhibiting companies and
over 51,000 attendees from
170 countries expected to
attend in-person and online
during the event.
For more information, visit
www.arabhealthonline.com.
PRINT
THIS ARTICLE
|